Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoladex 10.8 mg vs 3.6 mg in Chinese Early Breast Cancer
NCT03658213Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- Mar 2020
- Primary completion
- Nov 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Effective inhibition rate of serum estradiol(E2). Planned start Mar 2020; status: withdrawn.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03658213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658213.